To Assess Safety/Efficacy of ELAD in Subjects w/ Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure
A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD® in Subjects With Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure
Sponsor: Vital Therapies, Inc.
Terminated
Due to results from the VTI-208 study, the ELAD plan is being re-evaluated.
Other terminated trials from Vital Therapies, Inc.
More terminations from Vital Therapies, Inc.
A PHASE3 clinical study on Severe Acute Alcoholic Hepatitis, this trial is terminated or withdrawn. The trial is conducted by Vital Therapies, Inc. and has accumulated 11 data snapshots since 2014. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE3
▶ Show 6 earlier versions
-
Mar 2019 — Jan 2021 [monthly]
Terminated PHASE3
-
Jun 2018 — Mar 2019 [monthly]
Terminated PHASE3
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE3
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE3
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Apr 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Vital Therapies, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .